Epizyme, Inc. (NASDAQ:EPZM)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Thursday, November 2nd. They currently have a $25.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 94.55% from the company’s previous close.
Other equities research analysts also recently issued reports about the company. Royal Bank Of Canada set a $20.00 target price on Epizyme and gave the company a “buy” rating in a report on Saturday, August 5th. Jefferies Group LLC initiated coverage on Epizyme in a report on Wednesday, September 20th. They set a “buy” rating and a $23.00 target price on the stock. Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $26.00 target price on shares of Epizyme in a report on Tuesday, September 19th. Cann reiterated a “buy” rating and set a $26.00 target price on shares of Epizyme in a report on Tuesday, September 19th. Finally, Zacks Investment Research upgraded Epizyme from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a report on Wednesday, July 12th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $22.67.
Epizyme (NASDAQ EPZM) opened at $12.85 on Thursday. Epizyme has a twelve month low of $9.30 and a twelve month high of $20.45.
Epizyme (NASDAQ:EPZM) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.02. equities analysts predict that Epizyme will post -2.23 EPS for the current fiscal year.
In other news, insider Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of $15.68, for a total value of $235,200.00. Following the completion of the transaction, the insider now owns 22,228 shares in the company, valued at approximately $348,535.04. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director David M. Mott bought 200,000 shares of the firm’s stock in a transaction dated Monday, September 18th. The stock was purchased at an average price of $15.25 per share, with a total value of $3,050,000.00. Following the transaction, the director now owns 6,000 shares in the company, valued at approximately $91,500. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 45,000 shares of company stock valued at $733,950. 25.20% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently modified their holdings of the company. NEA Management Company LLC grew its position in shares of Epizyme by 3.2% in the 3rd quarter. NEA Management Company LLC now owns 6,460,851 shares of the biopharmaceutical company’s stock worth $123,079,000 after acquiring an additional 200,000 shares in the last quarter. Palo Alto Investors LLC boosted its position in Epizyme by 18.9% during the 2nd quarter. Palo Alto Investors LLC now owns 5,698,296 shares of the biopharmaceutical company’s stock valued at $86,044,000 after purchasing an additional 907,245 shares during the period. Vanguard Group Inc. boosted its position in Epizyme by 6.2% during the 2nd quarter. Vanguard Group Inc. now owns 3,419,844 shares of the biopharmaceutical company’s stock valued at $51,640,000 after purchasing an additional 200,982 shares during the period. State Street Corp boosted its position in Epizyme by 59.6% during the 2nd quarter. State Street Corp now owns 1,764,450 shares of the biopharmaceutical company’s stock valued at $26,644,000 after purchasing an additional 658,727 shares during the period. Finally, Point72 Asset Management L.P. acquired a new position in Epizyme during the 3rd quarter valued at approximately $17,591,000. Institutional investors own 78.00% of the company’s stock.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with our FREE daily email newsletter.